Relmada Therapeutics, Inc. (RLMD)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-06) · 99.1 · 99.2 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-12) · 99.1 · 99.2 | 8-K (2026-03-20) · 99.1 · 99.2 | ||
| 10-KLatest | FY-2025 | — | ||
| 10-Q | Q3-2025 | 8-K (2025-11-13) · 99.1 · 99.2 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-07) · 99.1 · 99.2 | ||
| 10-Q | Q1-2025 | — | ||
| 10-K | FY-2024 | 8-K (2025-03-27) · 99.1 | ||
| 10-Q | Q3-2024 | — | ||
| 10-Q | Q2-2024 | — | ||
| 10-Q | Q1-2024 | — | ||
| 10-K | FY-2023 | 8-K (2024-03-19) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-08) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover | ||
| Document and Entity Information | — |
|
| Audit Information | — |
|
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Condensed Consolidated Statements of Stockholders Equity (unaudited) | — |
|
| Consolidated Statements of Changes In Stockholders Equity | ||
| Consolidated Statements of Operations (P) | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accrued Expenses | ||
| Business | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Going Concern | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Options and Warrants | — |
|
| Other Post-retirement Benefit Plan | — |
|
| Other Postretirement Benefit Plan | ||
| Pay Vs Performance Disclosure | ||
| Prepaid Expenses | ||
| Segment Reporting | ||
| Stock Appreciation Rights | ||
| Stockholders Equity | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||